Study reports age-associated motor neuron mitochondrial degeneration precedes tongue muscle atrophy in rats

Researchers demonstrated that inflammaging-associated mitochondrial degeneration occurs in brainstem motor neurons prior to tongue muscle sarcopenia, suggesting a neurogenic origin for age-related aerodigestive dysfunction.

A study published in GeroScience evaluated systemic inflammaging, endoplasmic reticulum (ER) stress, mitochondrial structure, and motor neuron (MN) survival across the lifespan in Fischer 344 (F344) rats at 6, 18, and 24 months of age.

The researchers found that systemic inflammatory cytokines (TNFα, IL1β, and IL6) escalate from late-middle-age (18 months old). This rise is reflected in the brainstem earlier than in the tongue muscle.

In the brainstem and hypoglossal MNs, the ER stress response (pIRE1αS724), transcriptional activation of downstream genes (CDK5), mitochondrial fission (pDRP1S616), and mitochondrial oxidative capacity decline (SDHmax) were elevated at late-middle-age (18 months).

Hypoglossal MN numbers were reduced by 25% and 29% at 24 months compared to 6- and 18-month-old rats, respectively, with larger MNs being selectively vulnerable.

In contrast, the tongue muscle (genioglossus and longitudinalis) demonstrated resilience to inflammaging at 18 months, with ER stress, mitochondrial dysfunction, and muscle atrophy (a 33% reduction in genioglossus cross-sectional area and a 32% reduction in maximum tetanic force) delayed until old age (24 months).

The findings suggest that the age-related decline of tongue neuromuscular function—which contributes to clinical conditions such as dysphagia, impaired airway defense, and obstructive sleep apnea in elderly humans—is driven by a neurogenic cascade rather than localized myogenic failures.

By demonstrating that hypoglossal MN mitochondrial compromise and death precede tongue muscle weakness, the study establishes a chronological window of vulnerability.

This chronological gap suggests that therapeutic interventions aimed at preserving motor neuron mitochondrial homeostasis could effectively prevent downstream sarcopenia of critical aerodigestive muscle groups before physical symptoms manifest.

This shift toward a neurogenic model of sarcopenia suggests that pipeline candidates targeting systemic and central neuroinflammation may have therapeutic utility in muscle-wasting and frailty indications.

The study highlights the clinical relevance of protecting the complete motor unit, which could redirect translation strategies away from purely localized muscle anabolic therapies toward neuroprotective, anti-inflammatory, or mitochondrial-targeted small molecules.

Preclinical studies evaluating whether early administration of mitochondrial-targeted small molecules, fission inhibitors (such as DRP1 blockers), or anti-inflammatory drugs at late-middle-age can rescue hypoglossal motor neuron survival and preserve tongue muscle function.